Royalty Report: Drugs, HIV / AIDs, Disease – Collection: 178198

License Grant

U.S. Licensor and Owner in Ireland hereby jointly grant to Licensee the exclusive world rights to all present and future Patent Rights, Know-How and the Background Technology for all uses thereunder with the right to sublicense, to make, have made, use and sell the Products and Combination Products, and to practice, modifyand improve the Licensed Processes within the Field of Activity, in the Territory, and to sublicense others to do the same, all as herein provided.

License Property

Licensor has been assigned Owners rights in the Patent Rights and Know-How relating to the treatment of human/animal immunodeficiency as disclosed in U.S. Patent No. 4,956,355 entitled Agents for the Arrest and Therapy of Retrieval Infections, the said assignment allows Licensor sufficient portion of rights to grant licenses to make, use, exercise and vend the Products and Licensed Processes and Licensor has been granted an Investigational New Drug (IND) status from the U.S. Food and Drug Authority for the use of the technology outlined in the U.S. Patent No. 4,956,355 in the treatment of HIV infection, IND No. 31,980.

ANTI-VIRAL FORMULATION OF DEHYDROEPIANDROSTERONE (DHEA)'s s anti-retroviral effectiveness was shown through experiments which demonstrated in tissue culture that DHEA inhibited HIV replication.

Field of Use

This agreement has application in the medical and pharmaceutical and veterinary industries.

License Grant

The U.S. Licensor and Owner in Ireland hereby jointly grant to Licensee the exclusive world rights to all present and future Patent Rights, Know-How and the Background Technology for all uses thereunder with the right to sublicense, to make, have made, use and sell the Products and Combination Products, and to practice, modify and improve the Licensed Processes within the Field of Activity, in the Territory.

The amendments modify method and terms of the licensing fee.

License Property

Owner has developed a non-HIV based Anti-Serum which is capable of binding the HIV virus and removing it from the bloodstream.  The U.S. patents pending are 08/007,128 and 07/734,567.  There are patents/pending patents in various other countries.

Field of Use

'FIELD OF ACTIVITY' shall mean the use (including any use in connection with research, development, demonstration, testing or experimentation) of the Products for, or the manufacture, sale or other disposition of the Products for, human or animal therapeutic or prophylactic use within the Territory, including without limitation, any use for arrest and therapy of, or for vaccination against, retroviruses and bacterial infections.

License Grant

Pursuant to the terms of a certain License Agreement, by and between a University, the Licensors Designee in this agreement, and Licensor, the University and Licensor have agreed to grant Licensee a sublicense in certain inventions relating to ß-L-FD4C.

Licensor hereby grants to Licensee a non-transferable, worldwide, exclusive license under the Licensed Technology to make, have made, import, export, use, sell and have sold Licensed Products and practice the Inventions.

License Property

The University has licensed to Licensor certain inventions relating to, among other things, potential anti-viral compounds, including ß-L-FD4C.

The patents include
Novel L-23-Dideoxy Nucleoside Analogs as Anti-Hepatitis (HBV) Agents;
Reduced Toxicity Compositions and Methods for Treating HIV Infections; and,
Process for High Yield Diastereoselective Syntheses of Dideoxvnucleotides.

Field of Use

The field of use includes HIV treatments.

License Grant

Licensor grants an exclusive (even as to  Licensor), license under the Patent Assets and Know-How, including the right to grant sublicenses, to develop, make, have made, use, import, offer for sale, market and sell and otherwise dispose of Compound and Product, including any Improvements thereto, in the Territory.

License Property

The Licensed products contain the compound.  The Compound shall mean a condensation polymer of an aromatic sulfonic acid and an aldehyde or a pharmaceutically acceptable salt or prodrug thereof or a derivative, homolog, or analog thereof.

Field of Use

The Compound is for a candidate topical microbicide used to prevent infection by the human immunodeficiency virus (HIV) and other sexually transmitted pathogens.

License Grant

The University Foundation grants to Licensee the exclusive right and license to make, have made, use, import, offer for sale, and sell in the Territory, Licensed Products during the term of this Agreement including Licensee’s right to grant sublicenses.

The license granted is subject to a reserved, non-exclusive license of Foundation, transferable to University and its not-for-profit academic collaborators, to practice the Licensed Patents in the Field, only for the purpose of non-commercial scientific inquiry, academic research, and education.

License Property

Licensed Product means any compound, product, service, or process in the Field, the manufacture, use, or sale of which, but for the license granted herein, would infringe at least one Valid Claim.

Licensed Patents means (i) the patent applications listed, (ii) the United States patents that may issue from the patent applications listed and from divisionals and continuations and continuations-in-part of such United States patents and patent applications, (iii) all foreign counterparts of such patent applications, and all patents that issue thereon anywhere in the world, including reexamined and reissued patents. Licensed Patents shall also mean any patent application having claims in the Field directed to an invention made in the laboratory of Dr. Vasu Nair six months or less prior to the Effective date, and (iv) with respect to the matters described in clauses (i), (ii) and (iii) above, all provisionals, renewals, re-examinations, patents of addition, supplementary protection certificates, extensions, restorations of patent terms, letters of patent, registration or confirmation patents and reissues of such patents or patent applications.

7,250,421 – Diketo acids with nucleobase scaffolds anti-HIV replication inhibitors targeted at HIV integrase

Indication shall mean the prevention, treatment or diagnosis of a condition, infection or disease caused by or associated with a specific virus in the Field. For example HIV Indication means the prevention, treatment or diagnosis of a condition, infection or disease caused by or associated with Human Immunodeficiency Virus (HIV) and HCV Indication means prevention, treatment or diagnosis of a condition, infection or a disease caused by or associated with Hepatitis C Virus (HCV).

Field of Use

Field means any and all anti-viral uses, including but not limited to prophylaxis, diagnosis or treatment of a condition, infection or disease associated with a virus, except the Field specifically excludes any anti-viral use associated with (a) the following DNA virus families  poxviridae, polyomaviridae, papillomaviridae, adenoviridae, and parvoviridae; and (b) all RNA viruses except for the following RNA virus families, which are specifically included in the Field  retroviridiae (for example HIV as defined below), flaviviridae (for example HCV as defined below), orthomyxoviridae, paramyxoviridae, and coronaviridae. In the event that Licensee terminates the Sponsored Research Agreement (“SRA”), a copy of which is attached as Appendix J, pursuant to paragraph 16(d) of the SRA, the Field of this License Agreement shall automatically be amended to exclude HCV.